Skip to main content

Table 6 Mean change in forward wave amplitude (mmHg) after EMPA therapy separated according to median of different variables at baseline

From: How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial

Variable

Age

HbA1c

Copeptin

Heart rate

LDL-cholesterol

Uric acid

Systolic BP

hsCRP

≥ median

− 1.98 ± 5.31

− 2.14 ± 5.46

− 2.56 ± 5.60

− 1.86 ± 4.94

− 1.95 ± 6.47

− 2.23 ± 5.33

− 0.76 ± 5.10

− 1.31 ± 4.99

< median

− 1.19 ± 5.26

− 1.03 ± 5.07

− 0.81 ± 4.90

− 1.29 ± 5.65

− 1.27 ± 4.01

− 1.03 ± 5.21

− 2.30 ± 5.36

− 1.86 ± 5.58

p-value

0.585

0.442

0.225

0.692

0.638

0.406

0.287

0.708

  1. Data are given as mean ± SD
  2. hsCRP high sensitive C-reactive protein, LDL-cholesterol low density lipid cholesterol, heart rate 24-h ambulatory heart rate, systolic BP systolic 24-h ambulatory blood pressure